Doctors In Delhi Say “We Prefer Covishield Over Covaxin.”

Residential doctors in Delhi say out of the two vaccines available they would prefer Covishield over Covaxin.

The residential doctors at the Ram Manohar Lohia (RML) hospital on Saturday sat they wish to be administered with Serum Institute’s Covishield vaccine rather than Bharat Biotech’s Covaxin due to reasons like “apprehensions over lack of complete trail.” The government has underplayed such apprehensions by saying that “a lot of work” had gone in developing both the vaccines

According to a prominent news channel that spoke to a resident doctor today they said that they might not be a participant if huge numbers of Covaxin doses are used. In a letter to the medical superintendent of the facility the Resident Doctor Association wrote “Covaxin manufactured by Bharat Biotech is being preferred over Covishield manufactured by Serum Institute in our hospital…. We would like to bring to your notice that the residents are a bit apprehensive but the lack of complete trail in the case of Covaxin and might not participate in huge numbers thus defeating the purpose of vaccination.”

Covishield was developed by Oxford University and pharma major AstraZeneca and in India it is produced by Serum Institute of India in Pune. Covaxin has been produced by Bharat Biotech in collaboration with Indian Council of Medical Research (ICMR).